Swiss skincare company Galderma has agreed to buy ZO Skin Health, a US-based brand sold primarily through dermatologists, for $1.5 billion in cash. The acquisition is the latest in Galderma's series of so-called bolt-on deals — smaller purchases designed to slot into its existing portfolio of dermatology-focused products.
Bank of America, which follows the company, estimates that ZO generated about $330 million in sales over the 12 months to June 2026. That puts the price at roughly 4.5 times enterprise value to sales, a multiple that sits a bit below recent beauty industry transactions. The bank expects the deal to be neutral to Galderma's core earnings per share in 2027, then start adding to earnings from 2028 onward.
Why the deal makes sense
Galderma's strategy has been to buy brands that fit its existing doctor-focused sales network. ZO Skin Health is a natural fit: it sells through the physician channel, meaning dermatologists and other medical professionals recommend and sell the products directly to patients. That is a different route to market than the mass retail or department store channels used by many beauty brands.
According to Bank of America, ZO reaches about 16,500 doctors, some of whom may already have relationships with Galderma. That overlap could help Galderma cross-sell its other products to a broader base of physicians, potentially boosting revenue without having to build new distribution from scratch.
The deal also increases the scale of Galderma's Derma Skincare unit by roughly 20%, according to the bank. That is a meaningful jump for a division that is central to the company's growth story.
The financial picture: flat in 2027, then growth
For investors, the key number is not the headline price but what happens to earnings after the deal closes. Bank of America's view is that the acquisition will be neutral to core earnings per share in 2027. That is typical for deals like this, because integration costs and acquisition-related accounting — such as amortization of intangible assets — tend to weigh on results in the first year.
From 2028 onward, the bank expects the extra revenue to translate into higher profit, adding 33 to 45 basis points to Galderma's group growth over the 2028-2031 period. A basis point is one-hundredth of a percentage point, so this is a modest but steady boost to the company's overall growth rate.
This "flat first, then higher" pattern is common in M&A. The first year is often a cleanup year, as the buyer absorbs the target, integrates systems, and takes out costs. Only after that does the deal start to show its true earnings contribution.
What it means for investors
For Galderma shareholders, the deal puts 2028 earnings in the spotlight. The all-cash nature of the transaction means there is no dilution from issuing new shares, but it also means the company is spending a large chunk of cash that could have been used for other purposes.
The 4.5-times sales multiple is below recent beauty deals, which have sometimes fetched higher multiples. That could make the deal look reasonably priced — but only if the promised growth materializes. If ZO's margins hold up and the integration goes smoothly, the deal could be a clean extension of Galderma's growth story. If not, investors may question whether the price was justified.
Bank of America's framing — neutral in 2027, accretive from 2028 — shifts attention to the earnings bridge between those two years. Investors will be watching for signs that the integration is on track, such as cost savings and revenue synergies. They will also be looking at how much of the purchase price is allocated to intangible assets, which are amortized over time and can drag on reported earnings.
For everyday investors, this deal is a reminder that M&A often takes time to pay off. The headline numbers — the purchase price and the sales multiple — are just the starting point. The real test is whether the acquired brand can be integrated successfully and contribute to profits in the years ahead.
Galderma's move also highlights the ongoing consolidation in the skincare and beauty sector, where companies are willing to pay premium prices for brands with strong distribution and loyal customer bases. As consumer spending shows signs of wobbling, deals like this are a bet that premium, doctor-recommended products can hold up better than mass-market ones.
Investors will get more clarity when Galderma reports its next earnings, which will include the first full quarter with ZO under its belt. Until then, the focus will be on how quickly the company can deliver on the promised earnings uplift from 2028.
